Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathy Bansbach

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Lancet. HIV|January 6, 2025
Target product profile for cell-based and gene-based therapies to achieve a cure for HIVSharon R Lewin, Cathy Bansbach, Dominic Kemps, et al.
Molecular Therapy. Methods & Clinical Development|August 6, 2024
Consensus-driven target product profiles for curative sickle cell disease gene therapiesDaima Bukini, Julie Makani, Joseph McCune, et al.
Plos Medicine|January 4, 2017
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic ModelEmily A Kendall, Sourya Shrestha, Ted Cohen, et al.
The Lancet. HIV|December 3, 2020
Multi-stakeholder consensus on a target product profile for an HIV cureSharon R Lewin, Timothy Attoye, Cathy Bansbach, et al.
Nature Communications|May 19, 2021
Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimensNicholas D Walter, Sarah E M Born, Gregory T Robertson, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Lancet. HIV|January 6, 2025
Target product profile for cell-based and gene-based therapies to achieve a cure for HIVSharon R Lewin, Cathy Bansbach, Dominic Kemps, et al.
Molecular Therapy. Methods & Clinical Development|August 6, 2024
Consensus-driven target product profiles for curative sickle cell disease gene therapiesDaima Bukini, Julie Makani, Joseph McCune, et al.
Plos Medicine|January 4, 2017
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic ModelEmily A Kendall, Sourya Shrestha, Ted Cohen, et al.
The Lancet. HIV|December 3, 2020
Multi-stakeholder consensus on a target product profile for an HIV cureSharon R Lewin, Timothy Attoye, Cathy Bansbach, et al.
Nature Communications|May 19, 2021
Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimensNicholas D Walter, Sarah E M Born, Gregory T Robertson, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 1